Compare IONQ Inc (IONQ) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IONQ Inc vs Neurocrine Biosciences Inc — how do they compare? IONQ Inc trades at $39.89 (market cap $15.98B), while Neurocrine Biosciences Inc trades at $142.44 (market cap $14.36B). The key difference: IONQ Inc and Neurocrine Biosciences Inc are close in size by market cap, and IONQ Inc is more actively traded (22,848,240 versus 1,237,180). Which is the better fit depends on your goals — on Pluang, investors hold IONQ Inc for 33 Days and Neurocrine Biosciences Inc for 23 Days on average.
| IONQ | NBIX | |
|---|---|---|
Market Cap | $15.98B | $14.36B |
Volume | 22,848,240 | 1,237,180 |
Sector | Technology | Health |
52-Week High | $82.09 | $185.50 |
52-Week Low | $26.59 | $123.10 |
Typical Hold Time | 33 Days | 23 Days |
Enterprise Value | $13.92B | $14.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IONQ trades at $39.89, down 3.51% today, with a bearish technical signal from moving averages but bullish oscillators. The company reported revenue of $130.02M in 2025 but a net loss of $510.38M, with a high P/S ratio of 54.74. Recent news highlights Bank of America's Buy rating and $60 price target, citing IonQ's semiconductor-based quantum computing approach as a key growth driver.
The stock presents high-risk, high-reward potential with strong analyst optimism but faces significant execution risks amid widening losses. Upside depends on scaling quantum technology profitably, while downside risks include cash burn and competitive threats. The consensus price target of $62.75 suggests substantial upside if growth targets are met.
Neurocrine Biosciences (NBIX) trades at $142.44, down 0.72% with bearish technical signals but strong fundamentals including three consecutive quarterly EPS beats. The company shows robust profitability with 20.91% net margin and 22.09% ROE, supported by growing revenue from $2.9B to $3.4B projected. Recent news highlights pipeline development and conference participation.
Wall Street maintains strong bullish sentiment with 86% buy ratings and $204.18 consensus target, representing 43% upside. Key risks include INGREZZA pricing pressure in 2029 and execution challenges as the company diversifies beyond its main product. The stock offers growth potential but faces near-term technical headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About IONQ Inc
IonQ is a leader in quantum computing, developing world-class quantum systems. Its technology aims to solve complex problems across finance, healthcare, and materials science that are beyond classical computers.
Read more on IONQ →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
